Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod
Just 4 months after Sobi paid Novimmune $50 million in cash — and put $400 million up in milestones — for a rare disease drug called emapalumab, the FDA has followed up with a quick OK on marketing.
The drug is used to treat hemophagocytic lymphohistiocytosis, or HLH, which is an autoimmune condition in which cells become overactive, releasing molecules that spur inflammation. The FDA notes that symptoms include “fever, enlarged liver or spleen and decreased number of blood cells.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.